NCT01738698
- Objective
- Not yet disclosed
- Design
- Not yet disclosed
- Participants
- Not yet disclosed
- Primary endpoint
- Not yet disclosed
- Results
- Results not yet reported; trial terminated 22 June 2021
pharma · Diabetes Mellitus · Hemophilia A
Takeda
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 1993
- Employees
- 1,617
- Programs
- 1179
- Drugs
- 359
- Patents
- 1436
SPD489 40mg
Phase 3 · small molecule · Schizophrenia
SPD489 40mg is a small-molecule therapeutic candidate developed by Takeda for the treatment of schizophrenia. The program reached Phase 3 clinical development but was terminated, with the latest milestone recorded on 22 June 2021. The mechanism of action and specific molecular target have not been disclosed. As a Phase
Internal code SPD489-338
At a glance
- Sponsor
- Takeda
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Schizophrenia
- Status
- terminated
- Trials
- 1
Executive summary
SPD489 40mg is a small-molecule therapeutic candidate developed by Takeda for the treatment of schizophrenia. The program reached Phase 3 clinical development but was terminated, with the latest milestone recorded on 22 June 2021. The mechanism of action and specific molecular target have not been disclosed. As a Phase 3 program that did not advance to regulatory filing, SPD489 represents a discontinued development effort in Takeda's psychiatry portfolio. The termination occurred after Phase 3 initiation, suggesting potential efficacy, safety, or strategic considerations led to the discontinuation decision. No regulatory submissions or approvals have been achieved for this candidate.
Why this program matters
Schizophrenia remains a significant unmet medical need affecting approximately 1% of the global population, with substantial morbidity, mortality, and socioeconomic burden. Current antipsychotic therapies, while effective for many patients, are associated with tolerability challenges including metabolic effects, extrapyramidal symptoms, and cognitive impairment, driving continued demand for novel mechanisms. The competitive landscape for schizophrenia treatment includes established agents such as aripiprazole, paliperidone ER, and clozapine, alongside emerging therapies. SPD489's termination at Phase 3 suggests the program did not meet strategic or clinical thresholds for continued investment, potentially reflecting competitive positioning challenges or insufficient differentiation from existing treatments. The schizophrenia market remains substantial, with multiple approved agents and ongoing development of novel approaches. Takeda's decision to discontinue SPD489 reflects portfolio prioritization within a competitive therapeutic area where efficacy, safety, and tolerability profiles must demonstrate clear clinical or commercial advantage.
Drug intelligence
SPD489 is a small-molecule therapeutic candidate for schizophrenia. The specific mechanism of action, molecular target, and route of administration have not been disclosed in available sources. Related approved therapies in the schizophrenia treatment landscape include:
- Aripiprazole (dopamine D2 partial agonist)
- Paliperidone ER (dopamine D2 antagonist)
- Clozapine (atypical antipsychotic with multi-target activity)
- Iloperidone (dopamine and serotonin antagonist)
- PERSERIS (risperidone long-acting injection)
Patent status, first approval date, and detailed molecular characterization of SPD489 have not been disclosed.
schizophrenia
Also known as: schizophrenia 12, schizophrenia (disease), SCZD
Overview
A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.
Treatment landscape
ClinicalTrials.gov lists 2,921 registered studies for Schizophrenia (AACT aggregate).
Phase breakdown: NA (1,441), PHASE4 (414), PHASE3 (377), PHASE2 (297), PHASE1 (276), PHASE1/PHASE2 (52), PHASE2/PHASE3 (42), EARLY_PHASE1 (22)
Common investigational therapies:
- Placebo
- Aripiprazole
- Risperidone
- Olanzapine
- placebo
- risperidone
- Paliperidone ER
- Ziprasidone
- olanzapine
- Quetiapine
Disease data sourced from MONDO Disease Ontology (MONDO:0005090), Orphanet — schizophrenia, NCT00000371, NCT00000372, NCT00000374, NCT00000387, NCT00001192, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Clinical development timeline
- Phase 3TBD
Phase 3 initiation
SPD489-338 (NCT01738698) entered Phase 3 clinical development for schizophrenia.
- Phase 32021-06-22
Program terminated
SPD489 40mg development program was terminated; specific reasons not disclosed.
Competitive landscape
The schizophrenia treatment market includes multiple approved small-molecule antipsychotics with established clinical efficacy and safety profiles. Aripiprazole (Otsuka Beijing Research Institute) and paliperidone ER (Hospital Authority, Hong Kong) represent widely-used dopamine antagonists. Clozapine (Bright Minds Biosciences Inc.) remains the gold-standard treatment for treatment-resistant schizophrenia despite tolerability constraints. Iloperidone (Vanda Pharmaceuticals Netherlands B.V.) and PERSERIS (Indivior Pty Ltd) offer alternative mechanisms and formulations. Takeda itself markets vortioxetine, a multimodal antidepressant with potential psychiatric applications. The competitive environment is characterized by established efficacy benchmarks, extensive clinical experience, and well-defined safety profiles across multiple agents. SPD489's termination at Phase 3 suggests the program did not demonstrate sufficient clinical or commercial differentiation to justify continued development against this established competitive backdrop.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Clozapine | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Iloperidone | Vanda Pharmaceuticals Netherlands B.V. | small_molecule | approved |
| Ramelteon | Takeda | small_molecule | approved |
| PERSERIS | Indivior Pty Ltd | small_molecule | approved |
| INTENSIFY SZ | Disc Medicine | small_molecule | approved |
| Varenicline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Aripiprazole | Otsuka Beijing Research Institute | small_molecule | approved |
| Paliperidone ER | Hospital Authority, Hong Kong | small_molecule | approved |
| Vortioxetine | Takeda | small_molecule | approved |
| Valbenazine | NEUROCRINE BIOSCIENCES INC | small_molecule | approved |
| Minocycline | BRIGHT MINDS BIOSCIENCES INC. | small_molecule | approved |
| Dexmedetomidine | BioXcel Therapeutics | small_molecule | approved |
| ZIPRASIDONE HYDROCHLORIDE | — | Dopamine D2 receptor antagonist | Approved |
| TRIFLUOPERAZINE HYDROCHLORIDE | — | D2-like dopamine receptor antagonist | Approved |
| THIOTHIXENE | — | Dopamine D2 receptor antagonist | Approved |
| SAMIDORPHAN L-MALATE | — | Delta opioid receptor partial agonist | Approved |
| RISPERIDONE | — | Serotonin 2a (5-HT2a) receptor antagonist | Approved |
| QUETIAPINE FUMARATE | — | Serotonin 2c (5-HT2c) receptor antagonist | Approved |
| PROCHLORPERAZINE | — | Dopamine D2 receptor antagonist | Approved |
| PERPHENAZINE | — | Dopamine D2 receptor antagonist | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Regulatory intelligence
SPD489 40mg did not advance to regulatory filing. FDA approval status: not achieved. EMA approval status: not achieved. PMDA (Japan) approval status: not achieved. NMPA (China) approval status: not achieved. The program was terminated during Phase 3 development on 22 June 2021, prior to any regulatory submissions. No breakthrough designation, fast-track status, or other expedited regulatory pathways have been disclosed.
Clinical evidence summary
Key questions answered
What is SPD489 40mg used for?
SPD489 40mg was being developed by Takeda for the treatment of schizophrenia, but the program was terminated during Phase 3 clinical development in June 2021.
Is SPD489 approved by the FDA?
No. SPD489 was not approved by the FDA. The program was terminated at Phase 3, prior to any regulatory submission.
Who manufactures SPD489?
SPD489 was developed by Takeda Pharmaceutical Company Limited. No manufacturing partner or licensee has been disclosed.
What is the mechanism of action of SPD489?
The mechanism of action of SPD489 has not been disclosed in available sources.
What is the molecular target of SPD489?
The specific molecular target of SPD489 has not been disclosed.
What clinical trial supports SPD489?
SPD489 was evaluated in trial NCT01738698, which was terminated on 22 June 2021. Results have not been reported.
Why was SPD489 development terminated?
The specific reasons for termination have not been disclosed by Takeda. Possible factors include insufficient efficacy, safety concerns, or strategic portfolio prioritization.
What is the route of administration for SPD489?
The route of administration for SPD489 has not been disclosed.
What phase of development was SPD489 in when terminated?
SPD489 was in Phase 3 clinical development when the program was terminated on 22 June 2021.
Are there alternative antipsychotics to SPD489?
Yes. Approved antipsychotics for schizophrenia include aripiprazole, paliperidone ER, clozapine, iloperidone, and PERSERIS (risperidone long-acting injection), among others.
What is the unmet medical need in schizophrenia treatment?
Current antipsychotics, while effective, are associated with tolerability challenges including metabolic effects, extrapyramidal symptoms, and cognitive impairment, driving demand for novel mechanisms with improved safety and efficacy profiles.
Is SPD489 available for patient use?
No. SPD489 is not available for patient use. The development program was terminated and no regulatory approval was obtained.
What is the dosage of SPD489?
SPD489 was being evaluated at a 40mg dose in clinical trials, but the program was terminated before approval.
Does Takeda have other schizophrenia treatments?
Takeda markets vortioxetine, a multimodal antidepressant with psychiatric applications, though it is not a primary antipsychotic for schizophrenia.
When was SPD489 first disclosed?
The first disclosure date for SPD489 has not been documented in available sources.
What is the patent status of SPD489?
Patent status information for SPD489 has not been disclosed.
Entity relationship graph
SPD489 40mg → Drug → Target → Indication → Company → Trials → Competitors
Companies
Indication
Trials
Analyst insights
SPD489's termination at Phase 3 represents a strategic portfolio decision by Takeda, likely reflecting one or more of the following considerations:
- Competitive positioning: Insufficient differentiation from established antipsychotics (aripiprazole, paliperidone ER, clozapine) in efficacy, safety, or tolerability profiles to justify market entry and development investment.
- Clinical efficacy or safety: Phase 3 data may have failed to meet pre-specified efficacy thresholds or revealed safety signals inconsistent with the risk-benefit profile required for schizophrenia treatment.
- Portfolio prioritization: Takeda's broader psychiatry strategy may have shifted resources toward higher-priority programs or alternative mechanisms with greater commercial or clinical potential.
- Market dynamics: The schizophrenia market, while substantial, is mature and competitive; new entrants require compelling clinical advantages to achieve market penetration.
No further development milestones or regulatory catalysts are anticipated for SPD489. The program represents a discontinued development effort with no path to approval or commercialization currently disclosed.
Quick answers
Concise, citable answers optimized for AI answer engines.
- What is SPD489?
- Small-molecule antipsychotic candidate by Takeda for schizophrenia; terminated at Phase 3 in June 2021.
- Sponsor?
- Takeda Pharmaceutical Company Limited.
- Indication?
- Schizophrenia.
- Development phase?
- Phase 3 (terminated 22 June 2021).
- Modality?
- Small molecule.
- Mechanism of action?
- Not disclosed.
- Molecular target?
- Not disclosed.
- Route of administration?
- Not disclosed.
- FDA approval status?
- Not approved; program terminated before filing.
- EMA approval status?
- Not approved; program terminated before filing.
- Clinical trial NCT ID?
- NCT01738698.
- Trial results?
- Not reported; trial terminated June 2021.
- Partner or licensee?
- None disclosed.
- Dosage evaluated?
- 40mg.
- Key competitors?
- Aripiprazole, paliperidone ER, clozapine, iloperidone, PERSERIS.
- Competitive advantage?
- Not established; program terminated before demonstrating differentiation.
- Market availability?
- Not available; development terminated.
- Takeda's current psychiatry focus?
- Portfolio includes vortioxetine; SPD489 discontinued.
- Reason for termination?
- Not disclosed by Takeda.
- Future development plans?
- None; program terminated with no restart anticipated.
- Patent expiration?
- Not disclosed.
- Regulatory pathway pursued?
- Standard Phase 3; no expedited designation disclosed.
Evidence & sources
- ClinicalTrials.gov NCT01738698 (clinicaltrials)
- Source: phase (source_attribution)
- MONDO Disease Ontology (MONDO:0005090) (mondo)
- Orphanet — schizophrenia (orphanet)
- NCT00000371 (clinicaltrials_gov)
- NCT00000372 (clinicaltrials_gov)
- NCT00000374 (clinicaltrials_gov)
- NCT00000387 (clinicaltrials_gov)
- NCT00001192 (clinicaltrials_gov)
- AACT (ClinicalTrials.gov aggregate) (aact)
- ClinicalTrials.gov (clinicaltrials_gov)
- Open Targets Platform (opentargets)
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.